Clinical Trials Logo
  1. Home
  2. Scleroderma, Systemic
  3. NCT03041025

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Systemic Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis

Clinical Trial Summary

GSK2330811 is a humanized monoclonal antibody which is in development for systemic sclerosis (SSc), a rare autoimmune disease with high morbidity and mortality. Currently, there are no approved disease modifying therapies and it is an area of high unmet medical need. GSK2330811 has been shown to bind and neutralize Oncostatin M (OSM) that has been associated with fibrosis, vasculopathy and inflammation in a number of diseases. This multi-center, randomized, double-blind (sponsor open), placebo controlled, proof of mechanism study will be the first study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeat subcutaneous (SC) doses of GSK2330811 in male and female participants with diffuse cutaneous SSc (dcSSc). Participants with active disease and a disease duration of <= 60 months will be enrolled. Approximately 24 to 40 participants will be randomized across two sequential cohorts. Cohort 1 will evaluate a repeat-dose predicted to provide sub-maximal inhibition of OSM, leading to a dose escalation decision. Cohort 1 is planned to consist of at least 4 participants, randomized such that 3 participants will receive GSK2330811 100 milligram (mg) and 1 will receive placebo. Cohort 2 is planned to consist of at least 20 participants, randomized such that participants will receive GSK2330811 300 mg and placebo in a 3:1 ratio respectively. The duration of the study is up to 34 weeks including a screening period of up to 6 weeks, treatment period of 12 weeks and follow-up period of 16 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03041025
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date June 5, 2017
Completion date July 7, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03965780 - The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED) N/A
Terminated NCT02558543 - Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Phase 2
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Terminated NCT01445821 - Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial Phase 3
Recruiting NCT05878717 - A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Phase 3
Recruiting NCT03559465 - Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis. N/A
Not yet recruiting NCT03610217 - Pragmatic Clinical Trials in Scleroderma N/A
Completed NCT02655640 - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis N/A
Completed NCT05622578 - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma N/A
Recruiting NCT04804930 - Trichoscopy and Systemic Scleroderma
Completed NCT03675581 - A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Phase 1
Completed NCT03221257 - Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Phase 2
Recruiting NCT05559580 - A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms Phase 2
Completed NCT00442611 - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Phase 1/Phase 2
Completed NCT00001330 - Study of Silicone-Associated Connective Tissue Diseases N/A
Completed NCT02597933 - A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Phase 3
Not yet recruiting NCT05821335 - Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis N/A
Completed NCT00333437 - Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement N/A
Completed NCT00025818 - Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Phase 3
Not yet recruiting NCT05351060 - Novel Splinting Technique Using 3D Models N/A